Advertisement

Epitope specificity and functional characterization of factor VIII inhibitors

  • Dorothea Scandella
  • Craig Kessler
  • Pamela Esmon
  • Deborah Hurst
  • Suzanne Courter
  • Edward Gomperts
  • Matthew Felch
  • Richard Prescott
  • Recombinate and Kogenate Study groups
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 386)

Abstract

Alloantibodies that inactivate factor VIII (F.VIII) develop in up to 24% of hemophilia A patients given therapeutic infusions of F.VIII. The probability of inhibitor formation is greatest in individuals with severe hemophilia (<2% F.VIII antigen), but they may also occur in moderate or mild hemophiliacs.1 Autoantibodies with similar properties appear rarely in individuals with normal F.VIII levels. In both cases bleeding episodes are difficult to control.

Keywords

Light Chain Factor VIII Epitope Specificity Immunoprecipitation Assay Inhibitor Titer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    S. Ehrenforth, W. Kreuz, I. Scharrer, R. Linde, M. Funk, T. Güngör, B. Krackhardt, and B. Kornhuber, Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs, Lancet339:594#x2013;598 (1992).PubMedCrossRefGoogle Scholar
  2. 2.
    C.A. Fulcher, S. de Graaf Mahoney, J.R. Roberts, CK. Kasper, and T.S. Zimmerman, Localization of human factor fVIII inhibitor epitopes to two polypeptide fragments, Proc. Natl. Acad. Sci. USA 82:7728#x2013;7732 (1985).PubMedCrossRefGoogle Scholar
  3. 3.
    C.A. Fulcher, S. de Graaf Mahoney, and T.S. Zimmerman, FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting, Blood 69:1475#x2013;1480 (1987).PubMedGoogle Scholar
  4. 4.
    D. Scandella, M. Mattingly, S. de Graaf, and C.A. Fulcher, Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization, Blood 74:1618#x2013;1626 (1989).PubMedGoogle Scholar
  5. 5.
    J. Ware, M. Lo, S. de Graaf, and C. Fulcher, Epitope mapping of human factor VIII inhibitor antibodies by site-directed mutagenesis of a factor VIII polypeptide. Blood Coag. Fibrinol. 3:703#x2013;716 (1992).CrossRefGoogle Scholar
  6. 6.
    D. Scandella, L. Timmons, M. Mattingly, N. Trabold, and L.W. Hoyer, A soluble recombinant factor VIII fragment containing the A2 domain binds to some human anti-factor VIII antibodies that are not detected by immunoblotting, Thromb. Haemostas. 67:665#x2013;671 (1992).Google Scholar
  7. 7.
    M. Steinbuch and R. Audran, The isolation of IgG from mammalian sera with the aid of caprylic acid. Arch. Biochem. Biophys. 134:279#x2013;284 (1969).Google Scholar
  8. 8.
    D. Scandella, M. Mattingly, and R. Prescott, A recombinant factor VIII A2 domain polypeptide quantitatively neutralizes human inhibitor antibodies which bind to A2, Blood 82:1767–1775 (1993).PubMedGoogle Scholar
  9. 9.
    CK. Kasper, L.M. Aledort, R.B. Counts, J.R. Edson, J. Fratantoni, D. Green, J.W Hampton, M.W. Hilgartner, J. Lazerson, P.H. Levine, C.W. McMillan, J.G. Pool, S.S. Shapiro, N.R. Shulman, and J. van Eys, A more uniform measurement of factor VIII inhibitors, Thrombos. Diathes. haemorrh. 34:869#x2013;872 (1975).Google Scholar
  10. 10.
    D. Scandella, S. deGraaf Mahoney, M. Mattingly, D. Roeder, L Timmons, and CA. Fulcher, Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli, Proc. Natl. Acad. Sci. USA 85:6152#x2013;6156 (1988).PubMedCrossRefGoogle Scholar
  11. 12.
    M. Shima, D. Scandella, A. Yoshioka, H. Nakai, I. Tanaka, S. Kamisue, S. Terada, and H. Fukui, A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine, Thromb. Haemostas. 69:240–246 (1993.) Google Scholar
  12. 12.
    D.B. Smith and K.S. Johnson, Single-step purification of polypeptides expressed in Esherichia coli as fusions with glutathione S-transferase, Gene 67:31#x2013;40 (1988).PubMedCrossRefGoogle Scholar
  13. P. Lollar, D.C. Hill-Eubanks, and CG. Parker, Association of the factor VIII light chain with von Willebrand factor, J. Biol. Chem. 263:10451#x2013;10455 (1988).PubMedGoogle Scholar
  14. 14.
    PJ. Fay and T.M. Smudzin, Intersubunit fluorescence energy transfer in human factor VIII, J. Biol. Chem. 264:14005#x2013;14010 (1989).PubMedGoogle Scholar
  15. 15.
    J. Gitschier, W.I. Wood, M.A. Shuman, and R.M. Lawn, Identification of a missense mutation in the factor VIII gene of a mild hemophiliac. Science 232:1415#x2013;1416 (1986).PubMedCrossRefGoogle Scholar
  16. 16.
    M. Arai, M. Higuchi, S.E. Antonarakis, H.H.Jr. Kazazian, J.A.III Phillips, R.L. Janco, and L.W. Hoyer, Characterization of a thrombin cleavage site mutation (Arg 1689 to Cys) in the factor VIII gene of two unrelated patients with cross-reacting material-positive hemophilia A, Blood 75:384#x2013;389 (1990).PubMedGoogle Scholar
  17. 17.
    E.A. Padlan and E.A. Kabat, Modeling of antibody combining sites. Methods Enzymol. 203:3#x2013;21 (1991).PubMedCrossRefGoogle Scholar
  18. 18.
    P.A. Foster, CA. Fulcher, RA. Houghten, S. de Graaf Mahoney, and T.S. Zimmerman, A murine monoclonal anti-factor VIII inhibitory antibody and two human factor VIII inhibitors bind to different areas within a twenty amino acid segment of the acidic region of factor VIII heavy chain, Blood Coag. Fibrinol. 1:9#x2013;15 (1990).CrossRefGoogle Scholar
  19. 19.
    CA. Fulcher, K. Lechner, and S. de G.Mahoney, Immunoblot analysis shows changes in factor VIII inhibitor chain specificity in factor VIII inhibitor patients over time, Blood 72:1348#x2013;1356 (1988).PubMedGoogle Scholar
  20. 20.
    I.M. Nilsson, E. Berntorp, O. Zettervall, and B. Dahlback, Noncoagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIII in hemophilia A patients, Blood 75:378#x2013;383 (1990).PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1995

Authors and Affiliations

  • Dorothea Scandella
    • 1
  • Craig Kessler
    • 2
  • Pamela Esmon
    • 3
  • Deborah Hurst
    • 3
  • Suzanne Courter
    • 4
  • Edward Gomperts
    • 4
  • Matthew Felch
    • 1
  • Richard Prescott
    • 1
  • Recombinate and Kogenate Study groups
  1. 1.Holland LaboratoryAmerican Red CrossRockvilleUSA
  2. 2.George Washington University School of MedicineWashingtonUSA
  3. 3.Miles Inc., BerkeleyUSA
  4. 4.Baxter/HylandGlendaleUSA

Personalised recommendations